This page documents the priority claims and modern relevance of each of the eight papers published by H. B. F. Antaki between 1951 and 1967. Every claim rests on a primary source: the published papers, patent specifications verified at text level, and canonical review literature. The table is a scholarly reference record, not a summary.
All 25 pharmaceutical patents citing his work are verified at text level against USPTO, EPO, and WIPO databases, April 2026. Ten assignee families. Six countries. 1970–2016.
| Contribution | Year | Reference Paper | Priority Claim | Modern Relevance |
|---|---|---|---|---|
| Pyrido[1,2-a]pyrimidine structural correction | 1951 | J. Chem. Soc., 1951, 551–555 | First unequivocal proof of 4-oxo structure, correcting 40-year error (Palazzo 1911, repeated by Seide 1925, Crippa & Scevola 1937, Khitrik 1939). Confirmed by Adams & Pachter 1952. Described as "unequivocal synthesis" by Hermecz & Mészáros, Adv. Heterocycl. Chem. 33 (1983), cited at pages 251, 256, 264, 269, 319. | Core scaffold of kinase inhibitors. Cited in Pfizer US 4,041,163 and US 4,066,766. Referenced in Hermecz, Adv. Heterocycl. Chem. 73 (1999) as references 2 and 3 of 350. Listed in e-EROS (Wiley, 2001) as Reference 1(a).
Wikipedia: 4H-Pyrido[1,2-a]pyrimidin-4-one Wikidata: Hekmat Antaki (Q138809036) |
| Pyrimido[1,2-a]quinoline synthesis | 1951 | J. Chem. Soc., 1951, 551–555 | First reported synthesis of 1H-pyrimido[1,2-a]quinoline. Pfizer US 4,066,766 (1978): "The synthesis of a 1H-pyrimido[1,2-a]quinoline appears to have first been reported by Antaki et al." | Anticancer DNA intercalators, antivirals, fluorescent materials. The antischistosomal activity of the compound was documented by Pfizer in 1978, citing the 1958 JACS paper. |
| Thiazolo[3,2-a]pyrimidine synthesis | 1951 | J. Chem. Soc., 1951, 551–555 | First aromatic thiazolo[3,2-a]pyrimidine reported. Cited in Pfizer US 4,041,163 (1977): "The pyrimido[2,1-b]benzothiazole ring system was first reported by Antaki, et al." — declarative, no hedge. | Anti-inflammatory, antiviral, antibacterial scaffold. Cited in Pfizer, Mead Johnson, and CIBA patent filings. |
| Heterocyclic steroid derivatives | 1951 | J. Chem. Soc., 1951, 901–904 | First systematic fusion of quinoline, indole, pyrrole, thiazole, and benzimidazole to cholestane/allocholane scaffolds, designed for biological evaluation. Biological evaluation conducted at The British Drug Houses. | Steroid-quinoline hybrids as antimalarials; indolo-steroids as neurosteroid/anticancer candidates. Cited in Zhungietu & Dorofeenko, Russ. Chem. Rev. 36 (1967). |
| Halogenated glycosylbenzimidazoles | 1951 | J. Chem. Soc., 1951, 2873–2877 | First 5-chloro- and 5,6-dichloro-1-glycosylbenzimidazoles and first 2-methyl-1-glycosylbenzimidazoles. Novel glycosylation route via N-glycosyl-o-phenylenediamine and ethyl orthoacetate. Designed as vitamin B12 antagonists following Brink & Folkers (1949–1950). | Halogenated benzimidazole nucleosides as antiviral and antitumour candidates. Purine bioisostere concept. |
| UV chromophore assignment | 1958 | J. Am. Chem. Soc., 1958, 80, 3066–3069 | First systematic UV absorption standards for the pyrido[1,2-a]pyrimidine class. Identified constant absorption at 330–390 mμ and provided the mechanistic explanation. Confirmed by Shur & Israelstam, J. Org. Chem. 33 (1968). Adopted as standard reference by Hermecz & Mészáros (1983). Listed as Reference 1(a) in Wiley e-EROS (2001). | Diagnostic band used for metabolite identification and compound verification in pharmaceutical research. "This may be considered as evidence for the major contribution of zwitterionic fully aromatic structures such as VIII to the resonance state of the molecule." — Antaki, JACS 1958. |
| Schistosomicidal pyrido[1,2-a]pyrimidines | 1962 | J. Org. Chem., 1962, 27, 1371–1374 | First 2-methyl-3-cyano-4H-pyrido[1,2-a]pyrimidin-4-ones. Explicit schistosomicidal programme: "In continuation of previous work on the schistosomicidal activity in the pyrido[1,2-a]pyrimidine series." Submitted from home address, Agouza, Cairo — no institutional affiliation. | 2-Me-3-CN core in modern PI3K/CDK/JAK inhibitors. Antischistosomal evaluation of related scaffolds continuing (Oliveira et al., 2026). |
| Hexahydroquinoline synthesis — The Antaki Synthesis | 1963 | J. Chem. Soc., 1963, 4877–4879 | First practical three-component hexahydroquinoline synthesis via cyclohexane-1,3-dione condensation. Named the "Antaki Synthesis" in Oduselu et al., Front. Chem. 14 (2026) — listed as one of three classical methods alongside Hantzsch and Stankevich. Cited by Bossert & Vater (1989): "aroused our interest." Cited independently by USPTO examiner in Zeneca US 5,455,253 (1994). Seven ICI/Zeneca patents across USA, Europe, and Canada cite the paper for both compounds and reaction conditions. | Antimalarial candidate confirmed against P. falciparum (Vanaerschot et al., Nat. Microbiol. 2017). Cited in 25 pharmaceutical patents 1970–2016. Most recent: US9745274, Shin Nippon Biomedical Laboratories, Japan, granted 2017, expires 2034 — eighty-three years after the 1951 paper. |
| Decahydroacridine derivatives | 1965 | J. Chem. Soc., 1965, 2263–2264 | First 9,10-diaryl-1,8-dioxodecahydroacridines. Mechanistic proof of xanthene vs acridine interconversion. Bibliography cites Bongartz (1888) and Stobbe & Volland (1902) in the original German — the Partington bibliographic practice applied without interruption from London to Cairo across fifteen years. | Acridinedione core in calcium channel blockers, antitumour agents, and anti-leishmanial candidates. Cited in Acheson, Chemistry of Heterocyclic Compounds, Vol. 9 (1973), references 324 and 325. |
| Benz- and naphth-indenoquinolines | 1967 | J. Chem. Soc. (C), 1967, 1581–1582 | First benzindeno[2,1-c]quinolines and naphthindeno[1,2-b]quinolines via Wolff–Kishner reduction of the 8-oxo precursor. Paper received 18 July 1966. Product exhibited, in the paper's own words, "intense blue fluorescence." Eleven independent research groups (2011–2024) have reproduced the 8-oxo intermediate without completing the Wolff–Kishner step. | Fused indenoquinolines as anticancer topoisomerase inhibitors and DNA intercalators. Fluorescence properties relevant to OLED emitter chemistry and bioimaging probes. |
The following table documents novel ring systems and compounds explicitly claimed as new in the published papers, with primary source DOIs. Assembled so that researchers have direct access to the original literature. Every priority statement below is drawn verbatim or by direct structural reading from the paper cited.
| Compound or System | Paper and DOI | Priority Statement (from the paper) | First-Reported Compounds |
|---|---|---|---|
| Extended pyrido[1,2-a]pyrimidine ring systems | J. Chem. Soc., 1951, 551–555 10.1039/JR9510000551 |
"Reaction of 2-aminopyridine with ethyl β-aminocrotonate represents a novel and improved route to compounds of type (III). The reaction may be extended by employing other cyclic amidines." | 4:12-Dihydro-4-keto-2-methyl-1:12-diazaphenanthrene (V); 4:9-dihydro-4-keto-6-methyl-7:9-diazathianaphthen (VI) and 3-methyl analogue; 4:11-dihydro-4-keto-2-methyl-1:11-diaza-9-thiafluorene (VII) with six substituted variants (6-chloro, 6-amino, 6-carbethoxy, 6-ethoxy, 7:8-benzo, naphthothiazole); 4:11-dihydro-4-keto-2-methyl-1:11-diaza-9-oxafluorene (IX); cyclohexeno-oxafluorene (X); cyclohexeno- and cyclopenteno-triazafluorene variants (XII, XIII); imino-triaza compounds (XIV, XV). |
| Heterocyclic steroid derivatives — first series | J. Chem. Soc., 1951, 901–904 10.1039/JR9510000901 |
"Extension of this work to heterocyclic compounds has not hitherto been described in the literature." Revised linear structure for indolo(2':3':3:4)cholestane: "this conclusion must now be reversed." | Quinolino(3':2'-2:3)cholest-2-ene series (4'-hydroxy, 4'-chloro, 4'-amino, 4'-phenoxy); corrected linear indolo(2':3':3:4)cholestane (IV); ethyl 4'-methylpyrrolo(3':2'-2:3)cholest-2-ene-5'-carboxylate (V); androstane pyrrolo analogue (VI); 2'-aminothiazolo(5':4'-2:3)cholest-2-ene (VII); 1':9':11'-triazafluoreno(3':2'-2:3)cholest-2-ene (VIII). |
| Glycosylbenzimidazoles — novel N-glycoside route | J. Chem. Soc., 1951, 2873–2877 10.1039/JR9510002873 |
"The preparation of 1-glycosyl-2-methylbenziminazoles has not hitherto been recorded in the literature." Novel route: N-glycosyl-o-phenylenediamine + ethyl orthoacetate → isoacetanilide → glycosylbenzimidazole by dilute HCl. | 5-Chloro-1-β-D-glucopyranosylbenzimidazole; 5:6-dichloro series (D-ribityl, L-arabityl, D-sorbityl); 2-methyl-1-(β-D-glucopyranosyl)benzimidazole; 2:5-dimethyl-1-(β-D-glucopyranosyl)benzimidazole; xylopyranoside variants of 2-methyl and 2:5-dimethyl series. |
| 3-Acetyl and 3-cyano pyrido[1,2-a]pyrimidines; UV characterisation | J. Am. Chem. Soc., 1958, 80, 3066–3069 10.1021/ja01574a042 |
"A constant feature in the spectra of this class of compounds is the presence of a band with intense absorption in the region 330–390 mμ." First systematic UV characterisation of the pyrido[1,2-a]pyrimidine family. | 3-Acetyl- and 3-cyano-4-keto-4H-pyrido[1,2-a]pyrimidine; 9-methyl and 8-methyl variants; 3-cyano-4-keto-6,7-benzo-4H-pyrido[1,2-a]pyrimidine; ethyl 4-imino-8-methyl-4H-pyrido[1,2-a]pyrimidine-3-carboxylate; 3-cyano-2-keto-8-methyl-2H-pyrido[1,2-a]pyrimidine. Unexpected ring-nitrogen cyclization in 6-methyl-2-aminopyridine series documented. |
| Pyrido[1,2-a]pyrimidones — hyperconjugation and chromophore analysis | J. Org. Chem., 1962, 27, 1371–1374 10.1021/jo01036a021 |
"The effect of hyperconjugation on ease of cyclization is thus clearly evidenced." First identification of ~245 mμ band as the —C=C—C=O chromophore of the pyrimidine moiety, distinct from the ~350 mμ N-substituted pyridone-2-imine band. Published from home address, Agouza, Cairo — no institutional affiliation. | 2-Methyl-3-cyano-4H-pyrido[1,2-a]pyrimidine-4-one; 2,9-dimethyl and 2,8-dimethyl variants; 8-carboxamido-2-methyl-4H-pyrido[1,2-a]pyrimidine-4-one; 8-methyl-2,3-dihydro-4H-pyrido[1,2-a]pyrimidine-2,4-dione; 3-acetamido-2,3-dihydro-4H-pyrido[1,2-a]pyrimidine-2,4-dione and 8-methyl derivative. Spectra extended to thiazolo[3,2-a]pyrimidine-5-one and s-triazolo[2,3-a]pyrimidine-7-one. |
| Hexahydroquinoline synthesis and derived scaffolds | J. Chem. Soc., 1963, 4877–4879 10.1039/JR9630004877 |
"We have now found that… the monocyclic diketone condenses smoothly with aromatic aldehydes and ethyl β-aminocrotonate." Structure of xanthen (III) "proved by independent synthesis." Named the Antaki synthesis: Oduselu et al., Front. Chem. 14 (2026). | Ethyl 4-aryl-1,4,5,6,7,8-hexahydro-2-methyl-5-oxoquinoline-3-carboxylates (I), six aryl variants; ethyl 4-aryl-5,6,7,8-tetrahydro-2-methyl-5-oxoquinoline-3-carboxylates (II); 9-aryloctahydro-1,8-dioxoxanthens (III), structure proved by independent synthesis; 9-aryldecahydro-1,8-dioxoacridines (IV); 2-4'-nitrostyryl derivative of (II); phenylhydrazones and indoloquinoline rearrangement product. |
| Decahydroacridine derivatives and diol series | J. Chem. Soc., 1965, 2263–2264 10.1039/jr9650002263 |
"The latter [xanthen] is recovered unchanged after treatment with aromatic amines, indicating that the reaction does not proceed through the xanthen." Extension of 1963 condensation to aromatic amines. | 9,10-Diaryl-1,8-dioxodecahydroacridines (IV), multiple aryl combinations including β-naphthyl, p-chlorophenyl, o-hydroxyphenyl, p-methoxyphenyl variants; octahydroacridine (III) by chromium trioxide oxidation; 1,8-diols from xanthen (I), acridine (II), and diaryl acridine (IV) by thioglycolic acid reduction; 10-anilinoacridines (V) and their acid-catalysed reversion to xanthen documented. |
| Benz- and naphth-indenoquinolines | J. Chem. Soc. (C), 1967, 1581–1582 10.1039/J39670001581 |
"Only some derivatives of 12H-benz[f]-, 7H-benz[6,7]-, and 13H-benz[4,5]-indeno[1,2-b]quinolines have been synthesised, and the naphthindenoquinolines have not been reported." Two independent synthetic routes developed. Final paper received July 18th, 1966. | 7-Oxobenz[h]indeno[2,1-c]quinoline (I); 9-oxobenz[f]indeno[2,1-c]quinoline (II); 13-phenyl-, 13-o-nitrophenyl-, 13-p-nitrophenyl-12-oxobenz[f]indeno[1,2-b]quinoline; 7-phenyl- and 7-p-nitrophenyl-8-oxobenz[h]indeno[1,2-b]quinoline (III); 14-o-nitrophenyl- and 14-p-nitrophenyl-13-oxonaphth[2,3-f]indeno[1,2-b]quinoline (IV); Wolff–Kishner reduction product 7-phenyl-8H-benz[h]indeno[1,2-b]quinoline ("intense blue fluorescence"); Mannich bases (V), six aryl variants; 10,11-dihydro-9-oxo-N-(3-oxoinden-1-yl)benz[f]indeno[2,1-c]quinoline (VI). |
Full patent table with all 26 verified citations: see main page. Full reception record with direct quotations from patent specifications and review literature: In Their Own Words.